Skip to content

The multicenter study on heart failure treatment with intrathoracic impedance: MOMOTARO II study (MOnitoring and Management of OpTiVol Alert to Reduce heart failure hOspitalization)

The multicenter study on heart failure treatment with intrathoracic impedance: MOMOTARO II study (MOnitoring and Management of OpTiVol Alert to Reduce heart failure hOspitalization) - MOMOTARO II study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000012714
Enrollment
200
Registered
2013-12-27
Start date
2012-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient who has organic heart disease and requiring ICD or CRTD. Patient received ICD or CRTD. 1) Patient with less than 40% of LVEF 2) Patient with past history of heart failure

Interventions

Furosemide 10mg/day oral Nitroglycerin 10mg/day patch Education of life style

Sponsors

Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patient who has organic heart disease and requiring ICD or CRTD. Patient received ICD or CRTD. 1) Patient less than 40% of LVEF 2) Patient with past history of heart failure

Exclusion criteria

Exclusion criteria: 1) Patient under 20 years old. 2) Patient with moderate or severe chronic obstructive lung disease (forced expiratory volume < 1.0 L/s). 3) Patient who is received heart transplantation or is supposed to receive heart transplantation. 4) Patient with primary pulmonary hypertension. 5) Patient with renal failure of stage IV or V. (GFR <15 mL/min/1.73 m^2) 6) Patient under one year of life expectancy. 7) Patient with pregnancy or possible pregnancy. 8) Patient in whom doctor think inadequate. 9) Patient with heart failure in enrollment. 10) Severe heart failure patients with necessity of hospitalization

Design outcomes

Primary

MeasureTime frame
Comparison of intrathoracic impedance and BNP in OptiVol alert to that after 1 week

Secondary

MeasureTime frame
Comparison of other parameters in OptiVol alert to that after 1 week

Countries

Japan

Contacts

Public ContactAkihito Miyoshi

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of Cardiovascular Medicine

akihito344jp@yahoo.co.jp086-235-7351

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026